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Abstract  
 
Based on the material available in both the scientific literature and on the web, the 
present paper provides an updated pharmacological, chemical, toxicological and 
behavioural overview of Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-
2-aminopropane; „B-fly‟). B-Fly is a powerful, long lasting, LSD-like, hallucinogenic 
drug, which has been associated with a number of acute intoxications and fatalities in a 
number of countries. A critical discussion of the potential of misuse of B-fly but also of 
the methodological limitations, which are intrinsically associated with the analysis of 
online, non-peer reviewed, material, is presented. It is concluded that the availability of 
online information on novel psychoactive drugs, such as B-fly, may constitute a public 
health challenge. Better international collaboration levels may be needed to tackle this 
novel and fast growing phenomenon.  
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Introduction  
A new generation of psychoactive drugs related to the phenethylamines‟ group, known as 
the „FLY‟ drugs, emerged in the last few years as a new recreational drug misuse trend. 
The most common FLY compounds are: 
 
 2C-B-FLY: 1-(8-Bromo-2,3,6,7-tetrahydrobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-
aminoethane hydrochloride  
 3C-B-FLY: 1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-
aminopropane hydrochloride  
 Bromo-Dragonfly:   1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropane 
 
They are called „FLY‟ because their molecular structure resembles the insect: the body of 
the fly will be the benzene ring; the two wings are the furan or dihydrofuran rings; the 
head is the bromine atom and the tail is the isopropylamine [1].  
 
 
 
 
Figure 1  
 
1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropane hydrochloride (Bromo-Dragonfly) 
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In particular, Bromo-Dragonfly was first synthesized by Matthew A. Parker at Purdue 
University in 1998 and used as a novel brain research chemical with rats [2-5].
 
Although 
structurally and chemically it is related to phenethylamines, the phenyl ring of this 
molecule is bound between two dihydrofuran rings, giving it more potency and much 
longer duration of action than most other phenethylamines [6]. Its effects can last up to 1-
3 days [1]. A procedure based on liquid chromatography-mass spectrometry (LC-MS) has 
been described to identify a number of phenethylamines [7], including some of the „FLY‟ 
drugs such as 2C-B-Fly, in the urines of consumers using 3,4 
methylendioxypropylamphetamine (MDPA) as internal standard. Its mechanism of action 
is mediated primarily by agonist activity at the serotonin 5-HT2A receptors as well as to 
some degree at 5-HT1 receptor [2, 8]. It has been speculated that the interaction with both 
these receptors is likely to be responsible for the hallucinogenic effects [9-11]. Apart 
from 5-HT2A receptors, there is evidence from both biochemical [12] and behavioural 
[13-14]
 
studies that the 5-TH2C receptors‟ subgroups, in both rodents and humans, are 
involved as well in the pharmacodynamics of B-Fly [13-16].  
It has been observed that the synthesis of this substance is complicated by the fact that the 
molecule can form two distinct chiral or optical isomers and that originally 5 other related 
synthetic molecules are also called FLY
 
[17]. Although Bromo-Dragonfly is a research 
chemical and as such not for human consumption, in recent years it has been increasingly 
abused recreationally. Anecdotal evidence of this epidemic of misuse has emerged from 
an increased number of fatalities and hospitalizations [18-19], but also from the Internet. 
Indeed, hundreds of websites advertise the drug for sale and an increasing number of 
discussions and videos related to the substance are posted online on a regular basis [10-
23]. B-Fly is currently not legislated for under the UK Misuse of Drugs Act and is legally 
available in the UK, US and in most of Europe. Conversely, it is a controlled substance in 
Denmark, Sweden, Norway and Romania. 
We aimed at providing here a comprehensive overview of both the peer reviewed and the 
anecdotal online data on Bromo-Dragonfly. 
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Material and Methods 
The literature on Bromo-Dragonfly was searched in three databases, PsychInfo, Pubmed 
and MedScape. Key words used to carry out the database searches included: „1-(8-
bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropanehydrochloride‟, „Bromo-
Dragonfly, „B-fly‟ and „ABDF‟. Considering the limitation of peer reviewed, scientific, 
data results were integrated with a multilingual qualitative assessment of a range of 
websites, drug-forums and other online resources (e-newsgroups, chatrooms, mailing 
lists, e-newsletters, and bulletin boards). This was carried out using the Google search 
engine in 7 languages from a number of collaborating countries (UK, Finland, Norway, 
Belgium, Germany, Italy and Spain; see http://www.psychonautproject.eu). The online 
assessment was carried out over the period of one year (February 2009 - 2010) and 
involved the close monitoring of 203 websites. Of these, 108 were considered to be 
relevant for the present exercise and as such were monitored on a regular basis i.e., daily 
(n= 21), weekly (n= 32), or monthly (n= 53), depending on their relevance. The 
remaining 95 websites were considered not to bear any interest for the present study and 
thus were no longer monitored. Once the Bromo-Dragonfly was identified on these 
websites, further specific searches were carried for narratives focusing on the following 
issues: (a) the nature of its effects on users, including adverse reactions; (b) motivations 
behind its recreational use and possible trends of misuse, with particular attention to 
polydrug misuse/idiosyncratic combinations; (c) any other relevant information in the 
original language of the narratives. The full content of posts/sites of particular interest 
were also saved and copied onto a dedicated server using a specific programme [24]. This 
was carried out primarily for historical archiving and for allowing a more thorough and 
flexible content search using both MacOSX10.6 server built-in search capabilities [25] as 
well as a third-party search application
 
[26]. Data collected were stored in a password-
protected online database located within the coordinating centre (St. George‟s, University 
of London, UK) and a technical folder with all the available information on the effects of 
the drug, including various toxicological data, was also created. For the purpose of 
reporting results in this paper, any data collected from online forums, such as usernames 
and complete URLs for specific threads that were considered personal identifiable, were 
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anonymised. The study was cleared for ethical approval by the Wandsworth Local 
Research Ethics Committee, London, UK. 
 
Results 
 
Information on B-Fly online availability, consumption and manufacture  
Although the first reported case of recreational B-Fly abuse can allegedly be traced back 
to 2001
 
[23] but, according
 
to Google Insights for Search
 
[27], the web search activity 
associated with the substance has started to gradually increase only in 2005. Bromo-
Dragonfly was then formally identified in 2008 as a new emerging trend of drug abuse 
during the web monitoring activities of the Psychonaut Web Mapping Project following 
warnings from a number of EU countries, including Italy, Norway, Belgium, and Finland.  
„B-Fly‟ is typically sold online as blotter papers, liquid and less commonly as pills. 
According to most online reports, its primary route of administration is oral. After 
ingestion, the onset of its effects can be delayed for up to 6 hours. This delay has often 
led recreational users to ingest another dose of the substance thinking that the first dose 
was inadequate [28]. Alternatively, additional drugs may be ingested while waiting for 
the psychoactive effects to appear [20, 21, 22, 27, 28]. Although the exact dosage is still 
unknown, a „typical‟ dose is reported by users to be in the region of 200 to 800 μg [20]. 
There are two, or possibly more, types of B-Fly available on the Internet. The first one, 
called the „European Batch‟ (active at dose of 200 to 500 μg) and a less potent one, called 
the „American Batch‟  (active at 800 to 1800 μg) [17]. The average price for 1 gr of 
Bromo-Dragonfly is about 300 euros/420USD, while a single dose (blotter paper) is 
around 10-30 euros/14-42USD. Other items such as blotters sheets with various artworks 
are also widely available online [29]. 
 
Effects and adverse reactions 
Some users describe the effects of Bromo-Dragonfly as „a ride to the moon‟ because they 
„last too long and leave you drained‟ [20]. Accounts of experiences lasting 2-3 days after 
the consumption of a single dose (blotter paper) seem to be fairly common [20-21]. Some 
users report however that B-Fly is „definitely not for everyone, just too powerful‟ [21-
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22]. The drug can allegedly induce profound hallucinations (mainly visual distortions, 
such as geometric patterns and lights), sound alterations, but also other effects such as the 
sense of connection/belonging with other realities, sense of peace and well-being, 
emotional stimulation and meeting with entities, which are also common features of the 
so-called near-death experience [30].  
The level of toxicity associated to Bromo-Dragonfly may well be a reason of concern, as 
recently revealed by a series of hospitalizations and fatalities. For instance, a case of 
death was recorded in 2008 in a Swedish hospital, where the patient had convulsions, 
respiratory problems, liver and kidney failure and lost several fingers and toes. This 
incident was associated with the oral assumption of an allegedly very large amount of B-
Fly [18, 31].
  
Another fatality was recorded in Denmark after the ingestion of around 1ml 
of „LSD-like liquid‟, later identified as Bromo-Dragonfly [32]. The autopsy findings 
included oedema of the lungs, slight oedema of the brain, enlargement of the spleen, 
irritation of the mucous membrane in the stomach and ischaemic changes in the kidney 
[32]. Further fatalities have been recorded in Finland, Denmark, the UK, Norway and the 
US
 
[18,19]. Common adverse reactions may include:  nausea and vomiting, headache, 
tachycardia, elevated blood pressure, lung collapse, gastrointestinal disturbances, muscle 
tension, tremor, body temperature fluctuations, anxiety, panic attacks, arrhythmias, heart 
murmurs, slight pupil dilation, convulsions, stomach tightness, hallucinations, flashbacks, 
memory disturbances, confusion, and paranoid ideation [19, 33].  
 
Motivations for B-Fly intake and polydrug misuse issues 
Most users may approach Bromo-Dragonfly due to its „psychedelic‟ properties, which 
seem to be similar, but of longer duration, to those of lysergic acid diethylamide (LSD)
 
[20, 28, 34]. Other observations are however consistent with the misuser need of 
enhancing his/her physical sensations (e.g. taste, touch, hearing) and/or to prolong the 
sexual excitement/pleasure
 
[18]. Other reasons for taking B-Fly have been outlined in 
Table 1. 
Bromo-Dragonfly is often used in combination with a variety of other drugs, generally to 
enhance or prolong the duration of action of their effects. These polydrug misuse 
experimentations have led to a range of cases of acute intoxication; particularly worrying 
 8 
seems to be the combination of B-Fly with ketamine, with severe agitation, hallucinations 
and tonic-clonic seizures having been reported [19, 35, 36].  
 
Table 1: Overview of the alleged reasons for taking B-Fly  
 
Reasons 
 
Description 
Hallucinogenic/psychedelic effects „I nearly died from taking a £ 5 hit‟, 
claimed an 18-year old user, when he was 
promised a „mellow hit, similar to acid but 
more enjoyable‟  [36]. Effects of Bromo-
Dragonfly can include visual distortions, 
such as geometric patterns and lights, sense 
of belonging\connecting with other 
realities, and sense of unity with the 
cosmos among many others [28, 22, 20]. 
Experimenting with a new substance 
and/or with novel combinations 
 
B-Fly is reportedly often taken in 
combination with other compounds in order 
to try a different „high‟ [23, 22, 28], such 
as: 
 Alcohol 
 Prescribing drugs: alprazolam 
 Illicit/recreational drugs: 
hashish/marijuana; cocaine; 
amphetamines; LSD; ketamine 
 „Legal highs‟, including: Salvia 
divinorum; and Kratom (Mytragina 
speciosa) 
By mistake Large numbers of users have tried B-Fly 
thinking it was LSD, especially because 
both substances are available in the form of 
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blotter paper [20, 22].  
 
In 2009 there have been reports of users 
taking B-Fly by mistake thinking it was 
„2CB-fly‟ due to a mislabel batch sold 
online [22, 36]. 
 
„Thankful I am alive‟, said one these 
messages posted by a 23-year-old man: 
 „I was in a nearly catatonic state, unable 
and not wanting to move. Eyes closed the 
whole time. I couldn’t keep them open (…). 
It was 23°C outside, yet I was freezing. I 
was under all of the covers in my bed, yet I 
began sweating immensely. I couldn’t tell if 
I was awake or sleeping. Conscious or 
unconscious. It seemed I was somewhere in 
between the two. This scared me a bit. 
(After 50 hours) I still don’t feel normal. I 
hope I do soon" [20]
 
. 
Favourable legality status B-Fly remains a legal substance in a 
number of countries, although bans have 
recently been made in Denmark, Sweden, 
Norway and Romania. 
Online availability B-Fly is easy to purchase over the Internet, 
often at a discounted rate [29, 20, 22]. 
 
 
Discussion 
The present work provided a review of the current state of knowledge of Bromo-
Dragonfly in the peer reviewed literature. To the best of our knowledge, it also provided 
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for the first time a critical analysis of the information from and for web surfers/users 
relating to B-Fly psychoactive effects, adverse reactions and use in combination with 
other drugs. It seems from here that reasons behind Bromo-Dragonfly increase in 
popularity include: its powerful a long lasting, LSD-like, hallucinogenic effects; its 
favourable legal status; and its affordability. Indeed, B-Fly is at times promoted with 
special offers. Online popularity of B-Fly may have increased as a result of technical 
facilities such as: „alerts‟ about novel psychoactive products via text messages and/or 
instant messaging; and „e-mail this product to a friend‟ [37, 38]. 
Young/vulnerable individuals might be encouraged by a range of widely available online 
comments/messages/videos relating to the B-Fly intake experiences. This may be an issue 
of concern, if one considers that an estimated 61% of young European people aged 
between 15-24 years typically quote the Internet as a potential source of information on 
illicit drugs
 
[39]. Furthermore, it appeared from here that only a minority of drug selling 
websites were allegedly limiting access to the relevant links to under age individuals.  
At the time of writing, B-Fly remains legal in most of the EU countries. This may be an 
intriguing issue, given its chemical structure similarity with other, already controlled, 
phenethylamines such as 4-bromo-2,5dimethoxyphenethylamine (2C-B) and 4-bromo-
2,5-dimethoxyamphetamine (DOB). The current legal status of B-Fly may arguably 
facilitate the increasing levels of popularity of the drug, but might affect as well the 
users‟ perception of risks associated with its consumption. In fact, the idea that legality 
can equate with safety still remains well grounded amongst some recreational users [37, 
40, 41]. 
Most of the novel psychoactive compounds available online, such as B-Fly, share a 
number of characteristics that may constitute a public health challenge, including: (a) not 
being approved for human consumption; (b) their intake possibly being associated with a 
number of unknown side effects/adverse reactions); (c) very few related 
pharmacological/toxicological data being available in the peer reviewed, scientific, 
literature, with the limited knowledge being mostly restricted to pre-clinical studies; (d) 
rapidly appearing in always more sophisticated forms and remaining unregulated for a 
long period of time; (e) being most often synthesized in underground laboratories simply 
modifying the molecular structure of remaining controlled drugs (e.g. amphetamines; 
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tryptamines), hence raising further concerns in terms of presence of contaminating 
agents; (f) being largely available online and thus „just a click‟ away from our homes and 
potentially available to everyone; (h) being increasingly accepted as part of a „trendy‟ 
lifestyle, because the internet may arguably act as an enabler for niche activities to 
develop into social norms.  
A possible limitation of the present study could be given by the fact that only publicly 
available websites, forums and similar were monitored. Conversely, to improve the 
coverage of the study not only the web pages but also more private ways of 
communication (including newsgroups, chatrooms, mailing lists, newsletters, and bulletin 
boards) were here considered. A further limitation may be given by the fact that the 
present findings do rely mostly on what reported by users. In particular, we did not have 
any possibility here to understand if the substance the online B-Fly misusers were taking 
was indeed B-Fly. 
One could conclude that a constant level of web monitoring activities with respect to 
drug-related issues is a necessary step to better understand the level of the diffusion of 
novel psychoactive substances, such as B-Fly. From this point of view, better 
international collaboration levels may be needed to tackle this novel and fast growing 
phenomenon. Finally, it is suggested that the use of technological tools could be 
successfully incorporated in specific prevention programmes for novel compounds in the 
field of eHealth, as currently piloted by the Recreational Drugs European Network 
(ReDNet; http://www.rednetproject.eu) [41].  
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